Brief: Syndax Announces Additional Positive Data for Revuforj from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
09/12/2024 12:41
Dec 9 (Reuters) - Syndax Pharmaceuticals SNDX.O :
* SYNDAX ANNOUNCES ADDITIONAL POSITIVE DATA FOR REVUFORJ®
(REVUMENIB) FROM AUGMENT-101 TRIAL IN RELAPSED OR REFRACTORY
MNPM1 AML AND BEAT AML FRONTLINE COMBINATION TRIAL
* SYNDAX PHARMACEUTICALS: SUBGROUP ANALYSES FROM PH 2
PROTOCOL-DEFINED R/R MNPM1 AML EFFICACY POPULATION SHOW
RESPONSES ACROSS ALL MAJOR SUBGROUPS
* SYNDAX PHARMACEUTICALS INC -PLANS TO INITIATE PIVOTAL
TRIAL WITH
THIS COMBINATION IN FRONT-LINE NEWLY DIAGNOSED PATIENTS BY
YEAR-END 2024
Source text: ID:nPn6mgySda
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million